CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 51 enrolled
Drug / intervention
LY2189265 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01324388
NCT01324388Phase 1Completed

Pharmacokinetic and Pharmacodynamic Effect of LY2189265 on Lisinopril in Subjects With Hypertension and Metoprolol in Healthy Subjects

Eli Lilly and Company·interventional·Posted Mar 29, 2011·Updated Oct 8, 2014

In Brief

A Phase 1 clinical trial evaluating LY2189265, Metoprolol, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 51 participants across 3 sites.

Detailed Summary

The purpose of this study is twofold: 1. To evaluate the effect of LY2189265 on how the body absorbs a blood pressure lowering drug (lisinopril) in participants with high blood pressure who are currently taking lisinopril. 2. To evaluate the effect of LY2189265 on heart rate and blood pressure in healthy volunteers when taken with a Beta-blocker drug (metoprolol). In Part 1, participants will receive four weekly injections of LY2189265 with continued use of normal lisinopril therapy. Part 2 is a cross-over study design. Participants will receive a single injection of LY2189265 in one period, and seven daily doses of metoprolol and a single injection of LY2189265 in another period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 29, 2011
Enrollment StartMar 1, 2011
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.3 years ago

Interventions

LY2189265biological

Administered subcutaneously

Metoprololdrug

Administered orally

Lisinoprildrug

Administered orally

Placebodrug

Administered subcutaneously